Quote:

---

Third, we have finalized the protocol for a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s disease.
Ihttps://www.cytodyn.com/newsroom/press-releases/detail/633/december-2024-letter-to-shareholders

---